• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
  • FDA Grants Miltefosine Orphan Drug Designation for Treatment of GAE americanpharmaceuticalreview
    June 29, 2017
    Profounda announced it has received the US Food and Drug Administration's Orphan Drug Designation for the use of miltefosine to treat Granulomatous Amebic Encephalitis (GAE). Profounda licensed miltefosine (Impavido) from Knight Therapeutics.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service